组织驻留记忆T细胞(tissue-resident memory T cells,TRMs)作为一种特殊的记忆T细胞,在免疫应答中发挥着极其重要的作用。其特征是可表达归巢受体,从而具备驻留特性,因此能够驻留在外周组织器官中,当病原体侵袭时可以迅速反应。目前,TR...组织驻留记忆T细胞(tissue-resident memory T cells,TRMs)作为一种特殊的记忆T细胞,在免疫应答中发挥着极其重要的作用。其特征是可表达归巢受体,从而具备驻留特性,因此能够驻留在外周组织器官中,当病原体侵袭时可以迅速反应。目前,TRMs(尤其是CD8+TRMs)与肿瘤的关系及其在抗肿瘤中的应用被愈加重视,一方面是CD8+TRMs可以通过分泌颗粒酶B、穿孔素和INF-γ等因子直接杀伤肿瘤细胞,另一方面一些抗肿瘤措施(如放化疗、免疫治疗等)可以使CD8+TRMs在肿瘤组织中富集,从而进一步提高治疗的效果。本文就CD8+TRMs的亚群分类、在肿瘤中如何调控形成以及其在肿瘤治疗中的作用等方面的研究进展进行综述。展开更多
Neoantigen-targeted immunotherapy is a rapidly advancing field that holds great promise for treating cancer.The recognition of antigens by immune cells is a crucial step in tumor-specific killing,and neoantigens gener...Neoantigen-targeted immunotherapy is a rapidly advancing field that holds great promise for treating cancer.The recognition of antigens by immune cells is a crucial step in tumor-specific killing,and neoantigens generated by mutations in cancer cells possess high immunogenicity and are selectively expressed in tumor cells,making them an attractive therapeutic target.Currently,neoantigens find utility in various domains,primarily in the realm of neoantigen vaccines such as DC vaccines,nucleic acid vaccines,and synthetic long peptide vaccines.Additionally,they hold promise in adoptive cell therapy,encompassing tumor-infiltrating cells,T cell receptors,and chimeric antigen receptors which are expressed by genetically modified T cells.In this review,we summarized recent progress in the clinical use of tumor vaccines and adoptive cell therapy targeting neoantigens,discussed the potential of neoantigen burden as an immune checkpoint in clinical settings.With the aid of state-of-the-art sequencing and bioinformatics technologies,together with significant advancements in artificial intelligence,we anticipated that neoantigens will be fully exploited for personalized tumor immunotherapy,from screening to clinical application.展开更多
We sought to investigate the effects of epirubicin-nanogold compounds （EPI-AuNP） on hepatocellular carcinoma xenograft growth in nude mice. EPI-AuNP was prepared and hepatoma xenograft model was established in nude ...We sought to investigate the effects of epirubicin-nanogold compounds （EPI-AuNP） on hepatocellular carcinoma xenograft growth in nude mice. EPI-AuNP was prepared and hepatoma xenograft model was established in nude mice. The mice were then randomly divided into four groups： the control group with injection of saline, the AuNP treatment group, the EPI treatment group and the EPI-AuNP treatment group. After two weeks, the hepatoma weight and volume of the xenografts were assessed. Our transmission electron microscopy revealed that epirubicin- gold nanoparticles caused significantly more structural changes of hepatocellular carcinoma cells HepG2. The tumor weight in the Epi-AuNP treatment group （0.80 ± 0.11 g） was significantly lower than that of the control group （2.48±0.15 g）, the AuNP treatment group （1.67±0.17 g）, and the EPI treatment group （1.39±0.10 g） （P〈0.01）. Furthermore, the tumor volume of mice in the EPI-AuNP treatment group （0.27 ± 0.06 cm3） was significantly smal- ler than that of the control group （2.23 ± 0.34 cm3）, the AuNP treatment group （1.21 ± 0.25 cm3） and the EPI treat- ment group （0.81 ± 0.11 cm3） （P〈0.01）. In conclusion, epirubicin-nanogold compounds （EPI-AuNP） have significant inhibitory effects on the growth of hepatocellular carcinoma cells in vivo.展开更多
文摘组织驻留记忆T细胞(tissue-resident memory T cells,TRMs)作为一种特殊的记忆T细胞,在免疫应答中发挥着极其重要的作用。其特征是可表达归巢受体,从而具备驻留特性,因此能够驻留在外周组织器官中,当病原体侵袭时可以迅速反应。目前,TRMs(尤其是CD8+TRMs)与肿瘤的关系及其在抗肿瘤中的应用被愈加重视,一方面是CD8+TRMs可以通过分泌颗粒酶B、穿孔素和INF-γ等因子直接杀伤肿瘤细胞,另一方面一些抗肿瘤措施(如放化疗、免疫治疗等)可以使CD8+TRMs在肿瘤组织中富集,从而进一步提高治疗的效果。本文就CD8+TRMs的亚群分类、在肿瘤中如何调控形成以及其在肿瘤治疗中的作用等方面的研究进展进行综述。
基金This research was supported by the Clinical Frontier Technology Program of the First Affiliated Hospital of Jinan University,China(No.JNU1AF-CFTP-2022-a01223)Natural Science Foundation of Guangdong Province(2019A1515011763,2020A1515110639,2021A1515010994,2022A1515011695)Guangzhou Science and Technology Plan City-School Joint Funding Project(202201020084,202201020065).
文摘Neoantigen-targeted immunotherapy is a rapidly advancing field that holds great promise for treating cancer.The recognition of antigens by immune cells is a crucial step in tumor-specific killing,and neoantigens generated by mutations in cancer cells possess high immunogenicity and are selectively expressed in tumor cells,making them an attractive therapeutic target.Currently,neoantigens find utility in various domains,primarily in the realm of neoantigen vaccines such as DC vaccines,nucleic acid vaccines,and synthetic long peptide vaccines.Additionally,they hold promise in adoptive cell therapy,encompassing tumor-infiltrating cells,T cell receptors,and chimeric antigen receptors which are expressed by genetically modified T cells.In this review,we summarized recent progress in the clinical use of tumor vaccines and adoptive cell therapy targeting neoantigens,discussed the potential of neoantigen burden as an immune checkpoint in clinical settings.With the aid of state-of-the-art sequencing and bioinformatics technologies,together with significant advancements in artificial intelligence,we anticipated that neoantigens will be fully exploited for personalized tumor immunotherapy,from screening to clinical application.
文摘We sought to investigate the effects of epirubicin-nanogold compounds （EPI-AuNP） on hepatocellular carcinoma xenograft growth in nude mice. EPI-AuNP was prepared and hepatoma xenograft model was established in nude mice. The mice were then randomly divided into four groups： the control group with injection of saline, the AuNP treatment group, the EPI treatment group and the EPI-AuNP treatment group. After two weeks, the hepatoma weight and volume of the xenografts were assessed. Our transmission electron microscopy revealed that epirubicin- gold nanoparticles caused significantly more structural changes of hepatocellular carcinoma cells HepG2. The tumor weight in the Epi-AuNP treatment group （0.80 ± 0.11 g） was significantly lower than that of the control group （2.48±0.15 g）, the AuNP treatment group （1.67±0.17 g）, and the EPI treatment group （1.39±0.10 g） （P〈0.01）. Furthermore, the tumor volume of mice in the EPI-AuNP treatment group （0.27 ± 0.06 cm3） was significantly smal- ler than that of the control group （2.23 ± 0.34 cm3）, the AuNP treatment group （1.21 ± 0.25 cm3） and the EPI treat- ment group （0.81 ± 0.11 cm3） （P〈0.01）. In conclusion, epirubicin-nanogold compounds （EPI-AuNP） have significant inhibitory effects on the growth of hepatocellular carcinoma cells in vivo.
